ArticleBMC cancer2026
Simultaneous activation and late-stage inhibition of autophagy induces autophagy-dependent cell death in leukemia.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResistance to apoptosis is a major challenge in cancer therapy, especially in relapsed or refractory leukemia. Autophagy, a conserved lysosomal degradation pathway, plays a complex dual role: it can promote tumor survival under stress, yet its excessive activation can trigger autophagy-dependent cell death (ACD). This paradox has inspired a novel therapeutic strategy that simultaneously activates and inhibits specific stages of autophagy to push cells toward death. However, the molecular mechanisms underlying this approach remain poorly understood, particularly in non-solid tumors like leukemia.
methodsThis study investigated the effects of simultaneous autophagy activation and stage-specific inhibition on cell death in human Jurkat E6.1 leukemic T cells. Cells were treated with rapamycin (RAPA) to induce autophagy, combined with either chloroquine (CQ) to block late-stage degradation or 3-methyladenine (3-MA) to inhibit early-stage autophagosome formation. Cell viability was measured by MTS assay, while autophagy flux was evaluated using a combination of MDC staining, mCherry-eGFP-LC3 fluorescence imaging and Western blot analysis for LC3. To delineate the mode of cell death, we accessed apoptosis via caspase-3 cleavage and employed pharmacological inhibitors of apoptosis (z-VAD-FMK) and necrosis (Necrostatin-1).
resultsSimultaneous autophagy induction with RAPA and late-stage inhibition with CQ (RAPA + CQ) triggered massive autophagosome accumulation and significantly enhanced cell death. In contrast, early-stage inhibition with 3-MA (RAPA + 3-MA) prevented autophagic vesicle formation and abrogated the cytotoxic effect. Importantly, this cell death occurred independently of both apoptosis and necroptosis, suggesting a direct result of excessive and unprocessed autophagosomes, consistent with ACD.
conclusionIn conclusion, our findings demonstrate that trapping cells in a state of high autophagic flux through simultaneous induction and late stage inhibition, is a potent strategy to trigger non-apoptotic cell death in leukemia. This approach represents a promising therapeutic strategy to overcome apoptosis-resistant leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.